Search
引用和文献 (7)
Invitrogen™
ViraPower™ Adenoviral Gateway™ Expression Kit
Invitrogen 的 ViraPower™ 腺病毒表达系统 (ViraPower™ Adenoviral Expression System) 通过使用复制缺陷型腺病毒，在体外或体内将目的基因高效导入分裂和非分裂哺乳动物细胞中。了解更多信息
| 货号 | 数量 |
|---|---|
| K493000 | 1 kit |
货号 K493000
价格（CNY)
23,914.00
Each
数量:
1 kit
价格（CNY)
23,914.00
Each
Invitrogen 的 ViraPower™ 腺病毒表达系统 (ViraPower™ Adenoviral Expression System) 通过使用复制缺陷型腺病毒，在体外或体内将目的基因高效导入分裂和非分裂哺乳动物细胞中。 ViraPower™ 腺病毒表达系统 (ViraPower™ Adenoviral Expression System) 利用能简化克隆过程的 Gateway™ 重组克隆技术，这种技术可显著改进高滴度重组腺病毒的生成效率。 该试剂盒包含适用于 Gateway™ 的 pAd⁄CMV⁄V5-DEST 腺病毒载体，能够在人巨细胞病毒 (CMV) 即刻早期增强子⁄启动子作用下得到高水平蛋白表达；该试剂盒还包含 293A 细胞系。
主要优点：
• 生产高达 1 x 1011 pfu⁄ml 的高滴度腺病毒原液浓缩制剂
• 高效且快速的 Gateway™ 重组克隆技术避开了人或细菌细胞中低效率的同源重组
• 可在体外或体内将目的基因高效导入活跃分裂和非分裂哺乳动物细胞
• 适合高通量应用或文库转移应用
• 生产复制缺陷型病毒，提高系统的生物安全性，并使之成为更有用的基因导入工具。
主要优点：
• 生产高达 1 x 1011 pfu⁄ml 的高滴度腺病毒原液浓缩制剂
• 高效且快速的 Gateway™ 重组克隆技术避开了人或细菌细胞中低效率的同源重组
• 可在体外或体内将目的基因高效导入活跃分裂和非分裂哺乳动物细胞
• 适合高通量应用或文库转移应用
• 生产复制缺陷型病毒，提高系统的生物安全性，并使之成为更有用的基因导入工具。
仅供科研使用。不可用于诊断程序。
规格
构成或诱导系统组成型
输送类型腺病毒
适用于（应用）病毒表达
产品类型Adenoviral Expression Kit
数量1 kit
载体pAd
克隆方法Gateway
产品线Gateway, ViraPower
促进剂CMV
蛋白标记V5 Epitope Tag
Unit SizeEach
内容与储存
pAd⁄CMV⁄V5-DEST Gateway™ Vector: store at -20°C;.
293A Cells: store in liquid nitrogen.
Guaranteed stable for 6 months when properly stored.
293A Cells: store in liquid nitrogen.
Guaranteed stable for 6 months when properly stored.
常见问题解答 (FAQ)
可以使用BP Clonase酶和LR Clonase酶替代BP Clonase II 酶LR Clonase II酶进行BP/LR Clonase反应的一步法实验方案吗？
有推荐的一步式BP/LR重组实验方案吗？
如果丢失了入门克隆，如何将目的基因从一个Gateway兼容的表达克隆转移到一个新的目的载体？
我可以单独购买5X LR Clonase缓冲液或5X BP Clonase缓冲液吗？
是否提供用于在植物内表达的Gateway载体吗？
引用和文献 (7)
引用和文献
Abstract
The receptor for parathyroid hormone and parathyroid hormone-related peptide is hydrolyzed and its signaling properties are altered by directly binding the calpain small subunit.
Journal:Endocrinology
PubMed ID:15691895
'We show calcium-dependent, direct binding between the N-terminal portion of the PTH/PTHrP receptor (PTH1R) C-terminal intracellular tail and the calpain small subunit. Binding requires, but may not be limited to, amino acids W474, S475, and W477. The wild-type, full-length rat (r) PTH1R, but not rPTH1R with W474A/W477A substitutions, copurifies with
p116Rip targets myosin phosphatase to the actin cytoskeleton and is essential for RhoA/ROCK-regulated neuritogenesis.
Journal:Mol Biol Cell
PubMed ID:15469989
Activation of the RhoA-Rho kinase (ROCK) pathway stimulates actomyosin-driven contractility in many cell systems, largely through ROCK-mediated inhibition of myosin II light chain phosphatase. In neuronal cells, the RhoA-ROCK-actomyosin pathway signals cell rounding, growth cone collapse, and neurite retraction; conversely, inhibition of RhoA/ROCK promotes cell spreading and neurite outgrowth. The
Pulmonary interleukin-23 gene delivery increases local T-cell immunity and controls growth of Mycobacterium tuberculosis in the lungs.
Journal:Infect Immun
PubMed ID:16113296
Interleukin-23 (IL-23) is a heterodimeric cytokine that shares IL-12 p40 but contains a unique p19 subunit similar to IL-12 p35. Previous studies indicate a greater importance for intact IL-12/23 p40 expression than IL-12 p35 for immunity against Mycobacterium tuberculosis, suggesting a role for IL-23 in host defense. The effects of
Estrogen related receptors stimulate pyruvate dehydrogenase kinase isoform 4 (PDK4) gene expression.
Journal:J Biol Chem
PubMed ID:17079227
The pyruvate dehydrogenase complex (PDC) catalyzes the conversion of pyruvate to acetyl-CoA in mitochondria and is a key regulatory enzyme in the oxidation of glucose to acetyl-CoA. Phosphorylation of PDC by the pyruvate dehydrogenase kinases (PDK2 and PDK4) inhibits PDC activity. Expression of the PDK genes is elevated in diabetes
Cellular distribution, post-translational modification, and tumorigenic potential of human group III secreted phospholipase A2.
Journal:J Biol Chem
PubMed ID:15863501
Human group III secreted phospholipase A(2) (sPLA(2)-III) consists of a central group III sPLA(2) domain flanked by unique N- and C-terminal domains. We found that the sPLA(2) domain alone was sufficient for its catalytic activity and for its prostaglandin E(2) (PGE(2))-generating functions in various cell types. In several if not